Yaman Aylin, Selver Ozlem Barut, Saatci A Osman, Soylev Meltem F
Department of Ophthalmology, Dokuz Eylul University, Izmir, Turkey.
Clin Exp Optom. 2008 Nov;91(6):561-4. doi: 10.1111/j.1444-0938.2008.00287.x.
Non-arteritic anterior ischaemic optic neuropathy is the most common optic neuropathy of the elderly, characterised by unilateral, sudden, painless visual loss. No effective treatment has been proven to reverse or limit the course of this disease. We evaluated the role of intravitreal triamcinolone acetonide injection in eyes with non-arteritic anterior ischaemic optic neuropathy (NAION). Four eyes of four patients with acute NAION received a single intravitreal injection of triamcinolone acetonide (4 mg). The time between visual loss and intravitreal injection varied between four and 10 days. Mean age of patients was 57.25 years (range, 44 to 77 years). All patients experienced some visual gain. No complications related to the injection were observed during the following three months. Intravitreal triamcinolone injection may offer help in limiting the damage in this small group of patients with a relatively short history of visual loss due to NAION.
非动脉炎性前部缺血性视神经病变是老年人中最常见的视神经病变,其特征为单侧、突然、无痛性视力丧失。尚未证实有有效的治疗方法可逆转或限制该病的病程。我们评估了玻璃体内注射曲安奈德在非动脉炎性前部缺血性视神经病变(NAION)患者眼中的作用。4例急性NAION患者的4只眼接受了单次玻璃体内注射曲安奈德(4毫克)。视力丧失与玻璃体内注射之间的时间间隔在4至10天之间。患者的平均年龄为57.25岁(范围为44至77岁)。所有患者的视力均有一定程度的提高。在随后的三个月中未观察到与注射相关的并发症。对于这一小部分因NAION导致视力丧失病史相对较短的患者,玻璃体内注射曲安奈德可能有助于限制损伤。